Financial Performance - Q1 2024 revenue was CNY 1,044,651,488.68, a decrease of 4.87% compared to CNY 1,098,106,955.60 in the same period last year[8] - Net profit attributable to shareholders increased by 3.67% to CNY 19,245,988.18 from CNY 18,564,267.15 year-on-year[8] - Total operating revenue for Q1 2024 was RMB 1,044,651,488.68, a decrease of 4.9% compared to RMB 1,098,106,955.60 in the same period last year[25] - Net profit for Q1 2024 reached RMB 20,240,468.56, representing an increase of 1.9% from RMB 19,867,612.49 in the previous year[25] - The company reported a total profit of RMB 26,533,784.41, slightly up from RMB 26,485,438.25 year-on-year[25] - The company’s total comprehensive income for Q1 2024 was RMB -1,481,514.46, contrasting with RMB 18,878,980.49 in the previous year[25] Cash Flow - Operating cash flow net amount surged by 914.81% to CNY 43,926,318.16 compared to CNY 4,328,543.90 in the previous year[12] - The net cash flow from operating activities for Q1 2024 was RMB 43,926,318.16, a significant increase from RMB 4,328,543.90 in the same period last year, representing a growth of over 900%[26] - Total cash inflow from operating activities was RMB 1,035,579,556.57, down 8.4% from RMB 1,130,681,094.22 year-on-year[26] - Cash outflow from operating activities decreased to RMB 991,653,238.41, compared to RMB 1,126,352,550.32 in the previous year, marking a reduction of approximately 12%[26] - Cash inflow from financing activities was RMB 83,000,000.00, with a net cash flow of RMB 69,804,296.42, compared to a net outflow of RMB 9,799,182.44 in the previous year[26] Assets and Liabilities - Total assets increased by 4.63% to CNY 3,075,251,818.56 from CNY 2,939,079,216.37 at the end of the previous year[8] - Total liabilities reached RMB 1,078,018,427.29, up from RMB 940,293,365.01 at the start of the year[24] - Cash and cash equivalents stood at RMB 500,826,421.36, compared to RMB 458,889,059.10 at the beginning of the period[24] - Accounts receivable increased to RMB 681,850,963.62 from RMB 616,628,646.18[24] - Inventory decreased to RMB 645,754,367.53 from RMB 679,415,763.76[24] - Total equity attributable to shareholders was RMB 1,977,146,690.00, slightly up from RMB 1,975,931,610.49[24] Expenses - R&D expenses rose by 52.74% to CNY 13,503,276.08 from CNY 8,840,762.38 year-on-year[12] - Total operating costs for Q1 2024 were RMB 1,019,976,642.09, down 4.9% from RMB 1,072,140,614.54 year-on-year[25] - Tax expenses for Q1 2024 were RMB 6,293,315.85, a decrease from RMB 6,617,825.76 in the previous year[25] - The company’s sales expenses decreased to RMB 107,745,020.93, down from RMB 120,616,655.30 year-on-year, reflecting a cost control strategy[25] - The cash paid for purchasing goods and services decreased to RMB 717,462,102.43 from RMB 837,064,577.29, a decline of about 14.3%[26] - The cash paid to employees increased slightly to RMB 98,663,768.45 from RMB 95,439,684.58, showing a year-on-year increase of approximately 2.4%[26] Other Income and Comprehensive Income - Other income surged by 182.39% to CNY 1,365,149.84 from CNY 483,424.84 year-on-year[12] - The company reported a significant increase in investment income by 925.71% to CNY 510,984.88 from CNY 49,817.82 in the previous year[12] - Other comprehensive income after tax was RMB -21,721,983.02, compared to RMB -988,632.00 in the same period last year[25] - The company received RMB 243,140.16 in tax refunds, significantly higher than RMB 34,754.50 in the same period last year, indicating improved tax recovery[26] Accounting and Reporting - The company has not undergone an audit for the first quarter report[21] - The report indicates that the company is implementing new accounting standards starting from 2024[21]

证券代码：000705 证券简称：浙江震元 公告编号：2024-031 浙江震元股份有限公司 关于召开2023年年度网上业绩说明会暨向特定对象发行股 票相关事项说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 出席本次说明会的人员有：公司董事长吴海明先生、副董事长兼总经理柴军 先生、财务总监兼董事会秘书张誉锋先生、独立董事汪宏伟先生。 为充分尊重投资者、提升交流的针对性，现就公司 2023 年度网上业绩说明 会暨向特定对象发行股票相关事项说明会提前向投资者公开征集问题，广泛听取 投资者的意见和建议。投资者可于 2024 年 5 月 7 日（星期二）17：00 前访问 https://ir.p5w.net/zj/，或扫描下方二维码，进入问题征集专题页面。公司将 在本次业绩说明会上，对投资者普遍关注的问题进行回答。 欢迎广大投资者积极参与本次网上说明会。 （问题征集专题页面二维码） 特此公告。 浙江震元股份有限公司董事会 浙江震元股份有限公司定于2024年5月8日（周三）15:00-17:00在全景网举 办2023年度网上业绩说明会暨向特定对象发行股票 ...

浙江震元股份有限公司 2023 年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1. 本次股东大会出现否决议案，具体情况如下：议案 10《关于公司符合向特 定对象发行股票条件的议案》、议案 11.01《发行股票的种类和面值》、议案 11.02 《发行方式及发行时间》、议案 11.03《发行对象及认购方式》、议案 11.04《定价 基准日、发行价格与定价原则》、议案 11.05《发行数量》、议案 11.06《限售期》、 议案 11.07《募集资金金额及用途》、议案 11.08《上市地点》、议案 11.09《滚存 未分配利润安排》、议案 11.10《本次发行决议的有效期》、议案 12《关于公司向 特定对象发行股票预案的议案》、议案 13《关于公司向特定对象发行股票方案论证 分析报告的议案》、议案 14《关于公司向特定对象发行股票募集资金使用可行性分 析报告的议案》、议案 15《关于公司向特定对象发行股票涉及关联交易的议案》、 议案 16《关于公司与特定对象签署附条件生效的股份认购协议的议案》、议案 18 《关于向特定对象发行股票摊 ...

上海市锦天城律师事务所 关于浙江震元股份有限公司 2023 年度股东大会的 法律意见书 地址：上海市浦东新区银城中路 501 号上海中心大厦 11/12 楼 电话：021-20511000 传真：021-20511999 邮编：200120 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于浙江震元股份有限公司 2023 年度股东大会的 法律意见书 致：浙江震元股份有限公司 上海市锦天城律师事务所（以下简称"本所"）接受浙江震元股份有限公司 （以下简称"公司"）委托，就公司召开 2023 年度股东大会（以下简称"本次 股东大会"）的有关事宜，根据《中华人民共和国公司法》（以下简称《公司法》）、 《上市公司股东大会规则》等法律、法规、规章和其他规范性文件以及《浙江震 元股份有限公司章程》（以下简称《公司章程》）的有关规定，出具本法律意见 书。 为出具本法律意见书，本所及本所律师依据《律师事务所从事证券法律业务 管理办法》和《律师事务所证券法律业务执业规则（试行）》等规定，严格履行 了法定职责，遵循了勤勉尽责和诚实信用原则，对本次股东大会所涉及的相关事 项进行了必要的核查和验证，核查了本所认为出具该 ...

股票代码：000705 股票简称：浙江震元 公告编号：2024-019 浙江震元股份有限公司 关于为全资子公司震元医药提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、概述 浙江震元股份有限公司（以下简称"公司"）于 2023 年 12 月 26 日召开第十 一届董事会 2023 年第一次临时会议审议通过《关于为全资子公司震元医药担保的 议案》，同意公司为全资子公司绍兴震元医药经营有限责任公司（以下简称"震元 医药"）因生产经营实际需要借入的银行借款、承兑汇票等提供信用担保，12 个月 内累计担保总额不超过人民币 30,000 万元。担保额度的有效期自董事会批准同意 日起一年内，担保额度在授权期限内可循环使用。（具体内容详见公司于 2023 年 12 月 27 日在《证券时报》、《上海证券报》及巨潮资讯网 http://www.cninfo.com.cn 披露的《关于为全资子公司震元医药担保的公告》） 二、担保进展情况 2023 年 12 月 27 日，公司与中国工商银行股份有限公司绍兴分行（以下简称 "工商银行绍兴分行"）签署《最高额保 ...

Financial Performance - The company's operating revenue for 2023 was ¥4,106,371,505, a decrease of 0.94% compared to ¥4,145,479,305 in 2022[21]. - The net profit attributable to shareholders for 2023 was ¥81,642,566, representing a 4.79% increase from ¥77,831,563 in 2022[21]. - The net cash flow from operating activities increased significantly to ¥90,819,928, a 552.17% increase from -¥20,085,230 in 2022[23]. - The total assets at the end of 2023 were ¥2,939,079,216, reflecting an 8.99% decrease from ¥3,228,804,747 in 2022[23]. - The basic earnings per share for 2023 was ¥0.24, up 4.35% from ¥0.23 in 2022[23]. - The company reported a total of ¥3,430,105.46 in non-recurring gains and losses for 2023, down from ¥9,542,619.43 in 2022[27]. - Total revenue for 2023 was approximately CNY 4.11 billion, a decrease of 0.94% compared to CNY 4.15 billion in 2022[78]. - The pharmaceutical industry segment generated CNY 723.37 million, accounting for 17.62% of total revenue, with a year-on-year increase of 5.44%[78]. - The pharmaceutical commercial segment contributed CNY 3.38 billion, representing 82.38% of total revenue, with a decline of 2.21% from the previous year[78]. - The company achieved a total operating revenue of 4.106 billion yuan in 2023, a decrease of 0.94% compared to the previous year[65]. Dividend and Profit Distribution - The company plans to distribute a cash dividend of 0.60 RMB per 10 shares to all shareholders, based on a total of 334,123,286 shares[6]. - The board of directors has approved the profit distribution plan, which includes no bonus shares and no capital reserve conversion into share capital[6]. - The company reported a cash dividend of CNY 20,047,397.16, which represents 100% of the total profit distribution amount[156]. - The profit available for distribution to shareholders was CNY 364,179,539.92, indicating a positive profit for the reporting period[156]. - The company did not propose any stock dividends or capital increases during the reporting period[156]. Risk Management and Operational Challenges - The company faces various operational risks, including market competition and regulatory changes, which are discussed in detail in the management analysis section[6]. - The company has a comprehensive risk management strategy to address potential challenges in drug development and market dynamics[6]. - The company recognizes risks from industry policy changes and plans to adapt its strategies accordingly to mitigate operational risks[118]. - The company faces intensified market competition and aims to enhance its marketing network and drug service capabilities to expand market share[119]. - The company is aware of the risks associated with drug R&D and the lengthy process of bringing new products to market, which may impact innovation outcomes[119]. Research and Development - The company has a strong focus on research and development to innovate and enhance its product offerings in the pharmaceutical industry[6]. - The number of R&D personnel increased by 34.12% to 114, with a notable rise in the proportion of personnel holding bachelor's degrees[87]. - Research and development expenses increased by 6.25% to ¥46,157,291.31, accounting for 1.12% of total operating revenue[88]. - The company will strengthen collaboration with research institutions and increase R&D investment to accelerate drug innovation and consistency evaluation of generic drugs[120]. - The company is committed to developing a traceability system for traditional Chinese medicine to meet regulatory requirements and improve quality standards[116]. Market Position and Expansion - The company is actively expanding its market presence and exploring potential mergers and acquisitions to strengthen its competitive position[6]. - The company reported a significant expansion in its business scope, including drug wholesale, food sales, and medical device operations as of August 10, 2023[20]. - The company has diversified its product offerings to include special medical purpose formula foods and infant formula sales, reflecting a strategic focus on health-related products[20]. - The company is positioned to benefit from ongoing reforms in the pharmaceutical and healthcare system in China, which are enhancing regulatory frameworks and pricing mechanisms[31]. - The company ranked 37th among the top 100 pharmaceutical wholesale enterprises in 2022, highlighting its strong market position[49]. Corporate Governance - The company has established an independent governance structure that complies with relevant regulations and effectively safeguards steady development[125]. - The company maintains complete independence from its controlling shareholder in business operations, personnel management, asset ownership, institutional setup, and financial management[128]. - The company held its first temporary shareholders' meeting in 2023 on April 17, with an investor participation rate of 26.987%[129]. - The company reported a total of 12 proposals discussed in the annual shareholders' meeting, including financial reports and profit distribution plans[129]. - The company experienced a change in its board and management personnel, with several new appointments made on October 13, 2023[133]. Environmental and Social Responsibility - The company has successfully managed to operate its air pollution control facilities in accordance with the GB16297-1996 and DB33/310005-2021 standards, achieving compliance in all emissions[171]. - Zhenyuan Pharmaceutical has maintained a strong commitment to environmental protection, with no significant environmental incidents reported during the reporting period[170]. - The company has conducted nearly 200 community health events in the first half of the year as part of its social responsibility initiatives[174]. - The company actively participates in poverty alleviation and rural revitalization by collaborating with multiple herbal medicine planting bases in underdeveloped regions[176]. - The company has implemented a self-monitoring plan for emissions, regularly conducting tests on various pollutants to ensure compliance with environmental standards[173].

浙江震元股份有限公司 独立董事 2023 年述职报告（程幸福） 本人于 2023 年 10 月 13 日换届离任浙江震元股份有限公司（以 下简称"公司"）独立董事一职。在过去的任期内，本人根据《公司 法》、《关于在上市公司建立独立董事制度的指导意见》等有关法律法 规和《公司章程》的规定要求，认真履行独立董事职责，积极关注公 司的生产经营和业务发展，有效发挥独立董事的作用，努力维护公司 利益和全体股东尤其是广大中小股东的合法利益。现将本人 2023 年 度履职情况述职如下： 一、会议出席情况 本着勤勉务实和诚信负责的原则，本人积极参加公司召开的董事 会会议、股东大会以及董事会专门委员会会议，认真审阅会议材料， 积极参与各议题的讨论并提出合理建议，利用自己的专业知识对各项 议题进行客观谨慎的分析和判断，提出合理意见和建议，为公司做出 科学决策起到了积极的作用。在 2023 年度任职期间，本人出席董事 会会议 7 次、股东大会 3 次以及董事会专门委员会会议 9 次，对全部 议案经认真审议，均投出赞成票，没有反对、弃权的情形。 二、发表意见的情况 任期内，作为公司的独立董事，忠实履行职责，根据相关法律、 法规和规定 ...

浙江震元股份有限公司 2023 年度审计报告 目 录 | 一、审计报告……………………………………………………… 第 1—6 | | 页 | | --- | --- | --- | | 二、财务报表……………………………………………………… 第 7—14 | | 页 | | （一）合并资产负债表…………………………………………… | 第 | 7 页 | | （二）母公司资产负债表………………………………………… | 第 | 8 页 | | （三）合并利润表………………………………………………… | 第 | 9 页 | | （四）母公司利润表………………………………………………第 | | 10 页 | | （五）合并现金流量表……………………………………………第 | | 11 页 | | （六）母公司现金流量表…………………………………………第 | | 12 页 | | （七）合并所有者权益变动表……………………………………第 | | 13 页 | | （八）母公司所有者权益变动表…………………………………第 | | 14 页 | | | | 审 计 报 告 天健审〔2024〕418 号 关键审计事项是我们根据 ...

证券代码：000705 证券简称：浙江震元 公告编号：2024-012 浙江震元股份有限公司关于会计政策变更的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 浙江震元股份有限公司（以下简称"公司"）根据中华人民共和国财政部（以 下简称"财政部"）颁布的《企业会计准则解释第 16 号》（财会〔2022〕31 号， 以下简称"准则解释第 16 号"）相关规定变更会计政策，无需提交公司股东大 会审议，不会对公司财务报告产生重大影响。 一、会计政策变更的概述 （四）变更时间 公司根据《准则解释第 16 号》规定，自 2023 年 1 月 1 日起执行"关于单 1 （一）变更原因 2022 年 11 月 30 日，财政部发布了《准则解释第 16 号》，规定"关于单项 交易产生的资产和负债相关的递延所得税不适用初始确认豁免的会计处理"，自 2023 年 1 月 1 日起施行。公司根据上述要求对会计政策进行相应变更。 （二）变更前采用的会计政策 本次会计政策变更前，公司执行财政部《企业会计准则——基本准则》和各 项具体会计准则、企业会计准则应用指南、企业会 ...

证券代码：000705 证券简称：浙江震元 公告编号：2024-010 浙江震元股份有限公司日常关联交易公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、日常关联交易基本情况 （一）日常关联交易概述 2024 年度，公司预计向关联方浙江省诸暨市医药药材有限公司、太极集团 浙江东方制药有限公司采购、销售商品总额为 1,400 万元，向关联方绍兴震元健 康产业集团有限公司、绍兴智汇大酒店有限公司租赁房产等 300 万元。 2023 年度，公司关联方发生的关联交易金额为 1,430.78 万元。 | 关联交 | | 关联交 | 关联交易 | 2023年 | 2023年 | 上年发生 | | --- | --- | --- | --- | --- | --- | --- | | | 关联人 | | | 度预计 | 1-3月已 | | | 易类别 | | 易内容 | 定价原则 | 金额 | 发生金额 | 金额 | | | 浙江省诸暨市医 | 销售药 | 按照市场 | 1,000 | 54.40 | 946.58 | | 向关联 人销售 | 药药材有限公司 太极集 ...